PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

News

Review highlights benefits of PCSK9 inhibitor therapy but notes barriers to access US NLA guidance for FH includes PCSK9 inhibitors and bempedoic acid PCSK9 inhibitors benefit high risk patients with vulnerable plaques Evolocumab may improve gut health in patients with myocardial infarction FOURIER: Evolocumab cuts MACE risk in those with obesity and ASCVD American College of Cardiology emphasises PCSK9 inhibitor role for PAD in diabetes

American Heart Association Scientific Sessions 2026

Posted on 17 December 2025 |

Related content

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.